Results 31 to 40 of about 648 (164)

Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases [PDF]

Therapeutic Advances in Neurological Disorders
Background: With the development of highly effective disease-modifying treatments, vaccinations are becoming increasingly important in people with neurological autoimmune diseases.
Muriel Schraad, Mathias Mäurer, Anke Salmen, Tobias Ruck, Timo Uphaus, Vinzenz Fleischer, Felix Luessi, Maria Protopapa, Falk Steffen, Nicholas Hanuscheck, Katrin Pape, Tobias Brummer, Josef Shin, Thomas Korn, Luisa Klotz, Jan D. Lünemann, Marc Pawlitzki, Martin S. Weber, Antonios Bayas, Brigitte Wildemann, Hans-Peter Hartung, Florian Then Bergh, Clemens Warnke, Uwe K. Zettl, Achim Berthele, Aiden Haghikia, Ralf Linker, Hayrettin Tumani, Sven G. Meuth, Bernhard Hemmer, Heinz Wiendl, Tania Kümpfel, Ralf Gold, Stefan Bittner, Frauke Zipp   +34 more
doaj   +2 more sources

Effect of Diroximel Fumarate on gut dysbiosis and neuroinflammation

Neurotherapeutics
Sudhir Kumar Yadav, Ph.D., Naoko Ito, Shradha Suresh, Yaritza Rosario, Tamar Kalina, Sai L. Shankar, Ph.D., Kouichi Ito, Ph.D., Suhayl Dhib-Jalbut, M.D.   +7 more
doaj   +2 more sources

Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy. [PDF]

Neurodegener Dis Manag
Roman C, Garabedian M, Schobel VR, Schneider B, Luce E, Mendoza JP, Lewin JB, Shankar SL.   +7 more
europepmc   +2 more sources

Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis [PDF]

, 2022
Background: Dimethyl fumarate (DMF, Tecfidera®) is a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis. Lymphopenia is a frequent reason for discontinuation in fumarate-treated patients.
Andersen, Preben Borring, Góra, Monika Katarzyna, Jensen, Henrik Boye, Kant, Matthias, Ravn, Julie, Sejbaek, Tobias   +5 more
core   +2 more sources

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions [PDF]

, 2022
Multiple sclerosis; SARS-COV-2 vaccination; Humoral immune responseEsclerosis múltiple; Vacunación SARS-COV-2; Respuesta inmune humoralEsclerosi múltiple; Vacunació SARS-COV-2; Resposta immune humoralBackground: The impact of multiple sclerosis (MS ...
Bermel, Robert, Cohen, Jeffrey A, Grossman, Cynthia, Hersh, Carrie, Hyland, Megan, Montalban Gairín, Xavier, Mowry, Ellen, Tintore Subirana, Mar, Zabalza de Torres, Ana   +8 more
core   +4 more sources

Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes

Pharmaceuticals, 2022
Dimethyl fumarate (DMF) has emerged as a first-line therapy for relapsing-remitting multiple sclerosis (RRMS). This treatment, however, has been limited by adverse effects, which has prompted development of novel derivatives with improved tolerability ...
William R. Swindell, Krzysztof Bojanowski, Ratan K. Chaudhuri   +2 more
doaj   +1 more source

Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022 [PDF]

, 2022
Multiple sclerosis (MS), particularly relapsing MS (RMS), has become a treatable disease in recent decades, and immunotherapies are now able to influence long-term disease course.
Achtnichts, Lutz, Bigi, Sandra, Chan, Andrew, Derfuss, Tobias, Friedli, Christoph, Gobbi, Claudio, Hoepner, Robert, Kamber, Nicole, Kamm, Christian P, Kuhle, Jens, Lalive, Patrice, Müller, Stefanie, Papadopoulou, Athina, Pot, Caroline, Salmen, Anke, Zecca, Chiara   +15 more
core   +1 more source

Diagnoses of Multiple Sclerosis and Related Disorders and Disease-Modifying Therapies: A Comparison of the Danish Multiple Sclerosis Registry With Other Danish Health Registries. [PDF]

Brain Behav
This study aimed to describe and compare information on diagnoses of MS and related disorders as well as treatments with disease‐modifying therapies (DMTs) available in three national registries, highlighting the key differences relevant to MS research.
Joensen H, Framke E, Pontieri L, Magyari M.   +3 more
europepmc   +2 more sources

Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design

Biomedicines, 2023
Alzheimer’s Disease (AD) is a debilitating disease that leads to severe cognitive impairment and functional decline. The role of tau hyperphosphorylation and amyloid plaque deposition in the pathophysiology of AD has been well described; however ...
Robert Sharkus, Richa Thakkar, Dennis L. Kolson, Cris S. Constantinescu   +3 more
doaj   +1 more source

Klotho pathways, myelination disorders, neurodegenerative diseases, and epigenetic drugs [PDF]

, 2020
In this review we outline a rationale for identifying neuroprotectants aimed at inducing endogenous Klotho activity and expression, which is epigenetic action, by definition. Such an approach should promote remyelination and/or stimulate myelin repair by
Chen, Xiaohong, Faller, Douglas V., Glavas, Ioannis P., Harpp, David N., Kanara, Iphigenia, Kodukula, Krishna, Mavrakis, Anastasios N., Moos, Walter H., Pernokas, Julie, Pernokas, Mark, Pinkert, Carl A., Powers, Whitney R., Sampani, Konstantina, Steliou, Kosta, Vavvas, Demetrios G., Zamboni, Robert J.   +15 more
core   +1 more source